View Financial HealthCatalyst Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Catalyst Pharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0.4%자사주 매입 수익률총 주주 수익률0.4%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announces an Equity Buyback for $200 million worth of its shares.Oct 01모든 업데이트 보기Recent updatesCatalyst Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 11, 2026Apr 29Angelini Pharma Reportedly Explores A Potential Acquisition of Catalyst PharmaceuticalsApr 28Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2026Feb 26Catalyst Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 25, 2026Feb 11Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2025Nov 07Catalyst Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 05, 2025Oct 22Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announces an Equity Buyback for $200 million worth of its shares.Oct 01Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin PharmaceuticalsAug 26Catalyst Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2025Aug 07Catalyst Pharmaceuticals, Inc. Announces National Comprehensive Cancer Network Clinical Practice Guidelines in OncologyAug 06Catalyst Pharmaceuticals, Inc. Appoints Daniel Curran to the Board of DirectorsAug 05Catalyst Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 06, 2025Jul 22Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2000 Dynamic IndexJun 30Catalyst Pharmaceuticals, Inc. Announces Executive ChangesJun 03Catalyst Pharmaceuticals, Inc. Reaffirms Full-Year 2025 Revenue OutlookMay 08Catalyst Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025Apr 22Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 20, 2025Apr 14Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2025Feb 27Catalyst Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 26, 2025Feb 12Charles B. O’Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, IncJan 25Catalyst Pharmaceuticals, Inc. Announces Sub- Licensee DyDo Pharma Launches Firapse®? in JapanJan 21New minor risk - Share price stability Jan 09Catalyst Pharmaceuticals and SERB S.A. Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva PharmaceuticalsJan 09Third quarter 2024 earnings released: EPS: US$0.37 (vs US$0.29 loss in 3Q 2023) Nov 07Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024Nov 07Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024Oct 22Executive VP recently sold €2.7m worth of stock Aug 23New minor risk - Insider selling Aug 14Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024Aug 08Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024Jul 22Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSEMay 31Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024May 10First quarter 2024 earnings released: EPS: US$0.20 (vs US$0.28 in 1Q 2023) May 09Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024Apr 23Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024Apr 11Insider recently sold €380k worth of stock Mar 29Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)Mar 13Investor sentiment improves as stock rises 15% Mar 06Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024Feb 29Full year 2023 earnings released: EPS: US$0.67 (vs US$0.80 in FY 2022) Feb 29Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024Feb 15Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.Jan 05+ 1 more updateInvestor sentiment improves as stock rises 17% Dec 28Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo PharmaDec 18COO & Chief Scientific Officer recently sold €528k worth of stock Dec 08Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024Dec 05Catalyst Pharmaceuticals, Inc. Announces Management Changes, Effective on January 1, 2024Dec 04Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023Nov 10Third quarter 2023 earnings released: US$0.29 loss per share (vs US$0.22 profit in 3Q 2022) Nov 09Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSENov 04New minor risk - Share price stability Oct 31Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera PharmaceuticalsOct 28Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023Oct 24Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer ChangesOct 20Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for FirapseOct 14Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the BoardAug 27Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung CancerAug 17Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023Aug 10Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022) Aug 10Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive OfficerJul 26Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023Jul 25Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023Jul 13Investor sentiment improves as stock rises 15% Jun 22Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of DirectorsMay 31Investor sentiment deteriorates as stock falls 28% May 17First quarter 2023 earnings released: EPS: US$0.28 (vs US$0.13 in 1Q 2022) May 11Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023May 11Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per DayMay 10Full year 2022 earnings released: EPS: US$0.80 (vs US$0.38 in FY 2021) Mar 17Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023Feb 08+ 1 more updateInvestor sentiment improved over the past week Jan 17Investor sentiment improved over the past week Dec 23Independent Director recently sold €321k worth of stock Nov 16Third quarter 2022 earnings released: EPS: US$0.22 (vs US$0.10 in 3Q 2021) Nov 11Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022Nov 10Catalyst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022Oct 26Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric PatientsSep 30Chief Accounting Officer recently sold €734k worth of stock Sep 27Co-Founder recently sold €16m worth of stock Sep 16Investor sentiment improved over the past week Sep 14Chief Accounting Officer recently sold €970k worth of stock Aug 31Chief Commercial Officer recently sold €198k worth of stock Aug 24Investor sentiment improved over the past week Aug 16Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.12 in 2Q 2021) Aug 11Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022Aug 11Catalyst Pharmaceuticals, Inc., Annual General Meeting, Sep 19, 2022Aug 06Catalyst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022Jul 28Investor sentiment improved over the past week Jul 19Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022May 12First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.074 in 1Q 2021) May 11Catalyst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022Apr 26Catalyst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 16, 2022Mar 06Catalyst Pharmaceuticals, Inc. Further Strengthens FIRDAPSE® U.S. Patent PortfolioMar 04Investor sentiment improved over the past week Feb 10Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2022Feb 08Catalyst Pharmaceuticals Reports the FDA Marketing Approval Previously Granted for Ruzurgi® Is No Longer ValidFeb 04지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CN2 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CN2 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Catalyst Pharmaceuticals 배당 수익률 vs 시장CN2의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CN2)n/a시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.3%분석가 예측 (CN2) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CN2 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CN2 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CN2 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CN2 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/30 10:11종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Catalyst Pharmaceuticals, Inc.는 17명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBairdLuke HerrmannBairdJoel BeattyBaird14명의 분석가 더 보기
Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announces an Equity Buyback for $200 million worth of its shares.Oct 01
Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announces an Equity Buyback for $200 million worth of its shares.Oct 01
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin PharmaceuticalsAug 26
Catalyst Pharmaceuticals, Inc. Announces National Comprehensive Cancer Network Clinical Practice Guidelines in OncologyAug 06
Charles B. O’Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, IncJan 25
Catalyst Pharmaceuticals and SERB S.A. Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva PharmaceuticalsJan 09
Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSEMay 31
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)Mar 13
Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.Jan 05+ 1 more update
Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo PharmaDec 18
Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024Dec 05
Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera PharmaceuticalsOct 28
Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for FirapseOct 14
Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the BoardAug 27
Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung CancerAug 17
Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive OfficerJul 26
Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per DayMay 10
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric PatientsSep 30
Catalyst Pharmaceuticals Reports the FDA Marketing Approval Previously Granted for Ruzurgi® Is No Longer ValidFeb 04